Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)
Rani Therapeutics Holdings (RANI) posted quarterly Non-Current Debt of $2.2 million for Q2 2025, down 87.05% year-over-year from $17.2 million in Q2 2024, and down 62.35% quarter-over-quarter from $5.9 million in Q1 2025.
Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025) Analysis & Trends
Rani Therapeutics Holdings' Non-Current Debt history runs 5 years deep, the most recent figure standing at $2.2 million for Q2 2025.
- In Q2 2025, Non-Current Debt fell 87.05% year-over-year to $2.2 million; the TTM figure through Jun 2025 stood at $2.2 million (down 87.05% YoY), while the FY2024 annual figure was $9.6 million, down 60.74% from the prior year.
- Non-Current Debt for Q2 2025 stood at $2.2 million, down from $5.9 million in the prior quarter.
- The five-year high for Non-Current Debt was $29.3 million in Q2 2023, with the low at $2.2 million in Q2 2025.
- The 4-year median for Non-Current Debt is $19.0 million (2024), against an average of $18.6 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt soared 99.43% in 2023, then plunged 87.05% in 2025.
- Rani Therapeutics Holdings' Non-Current Debt stood at $29.1 million in 2022, then decreased by 16.0% to $24.5 million in 2023, then sank by 60.74% to $9.6 million in 2024, then plunged by 76.81% to $2.2 million in 2025.
- Business Quant data shows RANI's Non-Current Debt at $2.2 million in Q2 2025, $5.9 million in Q1 2025, and $9.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | 9.61 Mn |
| Sep 30, 2024 | 13.54 Mn |
| Jun 30, 2024 | 17.21 Mn |
| Mar 31, 2024 | 20.85 Mn |
| Dec 31, 2023 | 24.48 Mn |
| Sep 30, 2023 | 28.10 Mn |
| Jun 30, 2023 | 29.27 Mn |
| Mar 31, 2023 | 29.21 Mn |
| Dec 31, 2022 | 29.15 Mn |
| Sep 30, 2022 | 14.09 Mn |
| Dec 31, 2020 | 2.41 Mn |